Related Experiment Video

Updated: May 26, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies

S Fulda1

  • 1Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany. simone.fulda@kgu.de

Leukemia
|January 11, 2012
PubMed

Insights

Inhibitor of apoptosis (IAP) proteins promote cancer survival and treatment resistance. Targeting IAPs with new drugs shows promise for cancer therapy, with some treatments entering clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Resistance to apoptosis is a key feature of human cancers, leading to treatment insensitivity.
  • Inhibitor of apoptosis (IAP) proteins are crucial for cancer cells evading programmed cell death and promoting survival.
  • Elevated IAP expression in cancers, including hematological malignancies, correlates with poor prognosis.

Purpose of the Study:

  • To review the role of Inhibitor of Apoptosis proteins in cancer.
  • To discuss the development of therapeutic strategies targeting IAP proteins.
  • To provide an update on the clinical evaluation of IAP-targeting agents.

Main Methods:

  • Review of preclinical and clinical studies on Inhibitor of Apoptosis proteins.
  • Analysis of drug-discovery approaches, including small-molecule inhibitors and antisense oligonucleotides.
  • Examination of antitumor activities demonstrated in vitro and in vivo.

Main Results:

  • High expression of IAP proteins is linked to poor patient outcomes in various cancers.
  • IAP-targeting drugs, such as small-molecule inhibitors and antisense oligonucleotides, exhibit preclinical antitumor activity.
  • Several IAP-targeting strategies are progressing to clinical trials, particularly for leukemia.

Conclusions:

  • Inhibitor of Apoptosis proteins are significant therapeutic targets in oncology.
  • Targeting IAP proteins offers a promising strategy to overcome cancer's resistance to apoptosis.
  • Ongoing clinical evaluations indicate the therapeutic potential of IAP-neutralizing agents in cancer treatment.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...